Cognition Therapeutics, Inc. Income Tax Expense
Cognition Therapeutics, Inc. (CGTX) reported Income Tax Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-03-26
- Cognition Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2022-06-30 was -$125.00K.
- Cognition Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2022-03-31 was $125.00K.
- Cognition Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2021-03-31 was $0.00.
- Cognition Therapeutics, Inc. income tax expense (benefit) for fiscal 2025 was $0.00.
- Cognition Therapeutics, Inc. income tax expense (benefit) for fiscal 2024 was $0.00.
- Cognition Therapeutics, Inc. income tax expense (benefit) for fiscal 2023 was $0.00.
- Cognition Therapeutics, Inc. income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-26 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-03-26 | ||
| 2023-12-31 | $0.00 10-K · filed 2025-03-20 | ||
| 2022-12-31 | $0.00 10-K · filed 2024-03-26 | ||
| 2022-06-30 | -$125.00K 10-Q · filed 2023-08-08 | $0.00 derived: sum of 2 quarters · filed 2023-08-08 | |
| 2022-03-31 | $125.00K 10-Q · filed 2023-05-04 | ||
| 2021-12-31 | $0.00 10-K · filed 2023-03-23 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |